Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW...

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au
ABN: 90 009 237 889
ASX/Media Release (Code: PRR)
28th December 2011
UPDATE ON RESEARCH PROGRAM TO DEVELOP ORAL DELIVERY
SYSTEM FOR CERVICAL CANCER VACCINES
Australian healthcare company Prima BioMed Ltd (ASX: PRR) (Prima) is pleased to
Provide the following update on its research program to develop an oral delivery system
for cervical cancer vaccines.
Prima announced in November 2009 that it had engaged University of New South Wales
(UNSW) and University of Queensland (UQ) to undertake a research program to develop
an oral delivery system for vaccines for cervical cancer.
Prima can now advise that the research program has progressed to testing of various
formulations of a nanoparticle oral vaccine delivery system in a mouse model. Work
carried out to date has shown that a coated nanoparticle protein delivery system is
feasible and can be administered safely in a mouse model.
Work to be performed in 2012 by Professor Neil Foster and Professor Ian Frazer’s
laboratories will determine which oral formulation best delivers an immunogenic dose of
protein to the lower gastrointestinal tract.
The collaborative work will be supported in part by a competitive Australian Research
Council (ARC) grant. Such grants are determined on the merit of the research and are
highly sought after and regarded by the academic community.
The development of an oral delivery system for cervical cancer vaccines is potentially a
major breakthrough in drug delivery for cervical cancer treatment as it would provide a
suitable large scale alternative method of drug delivery to injection, which is currently the
prime method of delivery.
ENDS
For further information please contact:
Martin Rogers Mr James Moses
Chief Executive Officer Investor and Media Relations
Prima BioMed Mandate Corporate
Ph: +61 2 9276 1242 Ph: +61 (0) 420 991 574
E: [email protected] E: [email protected]